Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anti-Xa molecules]

B Boneu1

  • 1Laboratoire de recherche sur l'hémostase et la thrombose, hôpital Purpan, Toulouse.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Selective inhibition of factor Xa, a key enzyme in thrombin generation, demonstrates significant antithrombotic effects. Molecules like pentasaccharide, a synthetic ultra low molecular weight heparin, are advancing in development for thrombosis treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidelines of the French Society for Digestive Endoscopy (SFED).

Endoscopy·2006
Same author

The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies.

Journal of thrombosis and haemostasis : JTH·2005
Same author

Long-haul flights do not activate hemostasis in young healthy men.

Journal of thrombosis and haemostasis : JTH·2005
Same author

Laboratory monitoring of low-molecular-weight heparin therapy-part II.

Journal of thrombosis and haemostasis : JTH·2005
Same author

Enhancement of enzymatic fibrinolysis with 2-MHz ultrasound and microbubbles.

Journal of thrombosis and haemostasis : JTH·2004
Same author

[Oral anticoagulant treatment: practical aspects and significance of anticoagulant clinics].

Annales de cardiologie et d'angeiologie·2002

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Factor Xa is a critical enzyme in the coagulation cascade, central to thrombin generation.
  • Dysregulation of thrombin generation contributes to thrombotic disorders.

Purpose of the Study:

  • To investigate the antithrombotic potential of selective factor Xa inhibition.
  • To highlight the development of novel molecules targeting factor Xa.

Main Methods:

  • Development of molecules that either catalyze factor Xa inactivation (e.g., pentasaccharide) or directly inhibit factor Xa.
  • Evaluation of these molecules in preclinical models of thrombosis.

Main Results:

  • Selective factor Xa inhibition was shown to exert a significant antithrombotic effect.

Related Experiment Videos

  • Pentasaccharide, a synthetic ultra low molecular weight heparin, is a leading candidate in phase II development.

    • Conclusions:

    • Targeting factor Xa represents a promising therapeutic strategy for preventing thrombosis.
    • Novel anticoagulants with defined mechanisms of action are advancing clinical development.